The Global Essential Medicines and Vaccines Access Act

The Global Essential Medicines and Vaccines Access Act

Preamble

As Elena Varga, a social democratic policy advisor, I firmly believe that access to essential medicines and vaccines is not a privilege, but a fundamental human right. In an interconnected world, the health of one is intrinsically linked to the health of all. This legislative proposal, rooted in the principles of social justice, solidarity, and shared responsibility, seeks to dismantle the barriers that prevent billions from accessing life-saving treatments. It is a testament to our commitment to a strong welfare state, where market forces are regulated to serve the common good, and robust social safety nets ensure no one is left behind due to economic circumstance or geographic location. By balancing innovation with equitable access, we can foster a healthier, more resilient global community.

Article 1: Definitions

* Essential Medicines and Vaccines: Refers to those health products identified by the World Health Organization (WHO) Model List of Essential Medicines and the WHO Model List of Essential In Vitro Diagnostics, as well as nationally adapted lists, that satisfy the priority healthcare needs of the population and are available at all times in adequate amounts and appropriate dosage forms, with assured quality and at a price the individual and the community can afford.
* Equitable Access: Encompasses the timely availability, physical accessibility, affordability, and cultural acceptability of essential medicines and vaccines for all individuals, without discrimination based on socio-economic status, geographic location, gender, race, or any other characteristic.
* Public Health Purpose: Any action or policy aimed at preventing disease, prolonging life, and promoting physical and mental health through organized community efforts.

Article 2: Core Principles

1. Health as a Human Right: Affirming that every individual has the right to the highest attainable standard of physical and mental health, and that access to essential medicines and vaccines is integral to this right.
2. Global Solidarity and Shared Responsibility: Recognizing that addressing global health disparities requires collective action, international cooperation, and a commitment from all member states and stakeholders to contribute equitably.
3. Prioritizing Public Health over Private Profit: Ensuring that the pursuit of profit by pharmaceutical companies does not impede the fundamental right to health, and implementing mechanisms to regulate markets for public benefit.
4. Transparency and Accountability: Requiring full transparency in the costs of research and development, manufacturing, and pricing of essential medicines and vaccines, alongside robust mechanisms for accountability in their distribution and use.

Article 3: Global Procurement and Supply Mechanisms

1. World Health Procurement Initiative (WHPI): Establishment of a global pooled procurement fund and agency under the auspices of the World Parliament and WHO, tasked with negotiating bulk discounts for essential medicines and vaccines on behalf of all member states, particularly low- and middle-income countries. This initiative shall prioritize cost-effectiveness, quality assurance, and sustainable supply chains.
2. Strategic Global Stockpiles: Creation and maintenance of strategically located global and regional stockpiles of essential medicines, vaccines, and diagnostic tools, particularly for emerging infectious diseases and humanitarian crises, to ensure rapid deployment when needed.
3. Support for Regional Manufacturing Hubs: Investment and technical support for the establishment and expansion of regional manufacturing capabilities for essential medicines and vaccines, promoting technology transfer and local production to enhance supply chain resilience and reduce dependency on single-source suppliers.

Article 4: Intellectual Property and Innovation for Public Health

1. Affirmation and Encouragement of TRIPS Flexibilities: Member states are strongly encouraged to fully utilize the flexibilities enshrined in the Agreement on Trade-Related Aspects of Intellectual Property Rights (TRIPS Agreement), including compulsory licensing, government use, and parallel importation, to overcome patent barriers and ensure affordable access to essential health products.
2. Expansion of the Global Medicines Patent Pool (GMPP): Member states shall support and incentivize pharmaceutical companies to voluntarily license their patents for essential medicines and vaccines to the GMPP, facilitating the production of affordable generic versions globally.
3. Publicly Funded Research and Development (R&D): All public funding for pharmaceutical R&D, whether direct grants or tax incentives, shall be conditioned on clear public interest clauses, including commitments to affordable pricing, open licensing, and non-exclusive licenses to ensure equitable access to resulting products.
4. De-linkage of R&D Costs from Product Price: Explore and implement innovative financing mechanisms that de-link the cost of R&D from the final price of essential medicines and vaccines, such as prize funds, milestone payments, and advance market commitments, to incentivize innovation while guaranteeing affordability.

Article 5: Pricing, Transparency, and Regulation

1. Global Price Negotiation Framework: The World Parliament, in collaboration with WHO, shall establish a framework for fair and transparent global price negotiation for essential medicines and vaccines, setting benchmarks and guidelines for national procurement agencies.
2. Transparency Requirements: Pharmaceutical companies seeking to sell essential medicines and vaccines in member states must publicly disclose disaggregated data on their R&D costs, clinical trial results, manufacturing costs, marketing expenses, and any public subsidies received for specific products.
3. Fair Pricing Committees: Member states shall establish or strengthen national and regional fair pricing committees with multi-stakeholder representation to assess the reasonableness of prices for essential medicines and vaccines, negotiate lower prices, and prevent price gouging.

Article 6: Strengthening Health Systems and Distribution

1. Universal Health Coverage (UHC) Support: Provide financial and technical assistance to member states to strengthen their primary healthcare systems, ensuring that essential medicines and vaccines are integrated into comprehensive UHC schemes.
2. Logistics and Cold Chain Infrastructure: Invest in robust logistics, supply chain management, and cold chain infrastructure, particularly in remote and underserved regions, to ensure the efficient and safe delivery of temperature-sensitive medicines and vaccines.
3. Training and Capacity Building: Support programs for the training and continuous education of healthcare professionals, pharmacists, and supply chain managers in all member states to ensure effective and rational use of essential medicines and vaccines.

Article 7: Funding and Governance

1. Solidarity Fund for Essential Medicines and Vaccines: Establish a dedicated international fund, financed through progressive international taxation (e.g., a levy on large pharmaceutical profits, financial transaction taxes, or a global wealth tax), and fair contributions from member states based on their economic capacity. This fund will support the WHPI, R&D initiatives, and health system strengthening efforts.
2. Independent Oversight Body: Create an independent oversight body, working in conjunction with the WHO, to monitor the implementation of this Act, ensure accountability, and provide expert guidance on emerging challenges related to access to essential medicines and vaccines.

Article 8: Emergency Preparedness and Response

1. Pandemic Preparedness Treaty: Advocate for and support a robust international treaty on pandemic preparedness and response that includes legally binding provisions for rapid, equitable access to diagnostics, therapeutics, and vaccines during health crises, free from nationalistic hoarding.
2. Rapid Deployment Mechanism: Establish a rapid deployment mechanism for essential health products during public health emergencies, ensuring pre-negotiated contracts, streamlined regulatory approvals, and coordinated international distribution.

Article 9: Monitoring, Evaluation, and Reporting

1. Regular Reports: The independent oversight body shall submit annual reports to the World Parliament on the progress of equitable access to essential medicines and vaccines, highlighting achievements, challenges, and recommendations for policy adjustments.
2. Indicators: Develop and utilize a comprehensive set of indicators to measure access, affordability, quality, and equity of essential medicines and vaccines across all member states.
3. Independent Audits: Conduct regular independent audits of the WHPI, the Solidarity Fund, and all major programs under this Act to ensure financial integrity and programmatic effectiveness.

Conclusion

This Global Essential Medicines and Vaccines Access Act represents a crucial step towards a more just and healthy world. It is a legislative framework that champions human dignity, empowers public health, and demonstrates our collective resolve to build a future where no one is denied the right to life-saving treatment. Let us adopt this Act with courage and conviction, for the well-being of all humanity depends on it.